Pfizer, Inc.(PFE) - Stock detail

Pfizer, Inc.

US
PFE
Pfizer Inc.(Listing date: 01/17/1944)

Pfizer Inc. was incorporated under the laws of Delaware on June 2, 1942. It is a research-based global biopharmaceutical company. Using science and global resources, the company brings therapies that extend and significantly improve people's lives through the discovery, development, manufacturing and distribution of healthcare products, including innovative medicines and vaccines. The company operates in both developed and emerging markets, committed to advancing health, prevention, treatment and cure for the world's most feared diseases of our time. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare services worldwide.

AI Rating

Rating methodology
Latest close (chg%)26.17+2.23%
Buy price
26.60
Target price27.50
Sell price25.45
P/E TTM19.48
P/E18.50
Confidence70%
Risk score50/100
AI Summary
The analysis concludes a HOLD is the optimal risk-managed stance. While technicals show improvement (bullish MACD crossover, price above short-term EMAs) and sentiment has shifted (RBC upgrade, FDA approval), immediate and significant resistance at $26.33-$26.59 combined with a very low ADX (8.52) indicating a weak trend advises against a new buy. The high dividend yield (6.7%) supports holding for existing shareholders while awaiting a confirmed breakout above $26.60 for a potential move to the $27.50 target. Fundamental headwinds (declining revenue, high debt) balance the near-term catalysts.

Alpha Score

0-10
  • Trend（Score 0/10）

    No summary available

  • Valuation（Score 5/10）

    Pfizer appears fairly valued at the current price of $26.17, with P/E ratios slightly above historical norms but justified by the company's market position. The valuation metrics suggest no strong signal of significant undervaluation or overvaluation.

  • Financial strength（Score 6/10）
    Pfizer shows mixed financial health with adequate short-term liquidity but moderate leverage, operating as a solvent company with significant debt levels common for pharmaceutical companies funding R&D and acquisitions.
  • Profitability（Score 4/10）
    Pfizer's profitability is stable but declining as the company navigates post-pandemic normalization, with high gross margins being a strength but modest returns on capital indicating challenges in translating margins to superior earnings.
  • Sentiment（Score 0/10）
    No summary available
Latest price
$26.17+2.23%
Market cap148.98B
P/E TTM19.48
P/E18.50
Volume45.19M
Turnover1.17B